Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 4% in the quarter despite declines for REMICADE and ZYTIGA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
1Q Revenues: $20.0 billion (flat)
1Q Earnings: $3.7 billion (-14%)
Comments: Pharmaceutical sales were $10.2 billion in the quarter, up 4% driven by driven by STELARA, up 32% to $1.4 billion, IMBRUVICA, up 34% to $784 million, DARZALEX, up 46% to $629 million, TREMFYA, with sales of $217 million, INVEGA SUSTENNA, up 14% to $790 million, PREZISTA, up 10% to $523 million, partially offset by declines in REMICADE, down 21% to $1.1 billion, and ZYTIGA, down 20% to $679 million.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters